Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:oxazolidinone
gptkb:antibiotic |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2000 |
| gptkbp:ATCCode |
J01XX08
|
| gptkbp:bioavailability |
nearly 100% (oral)
|
| gptkbp:brand |
gptkb:Zyvox
Zyvoxid |
| gptkbp:CASNumber |
165800-03-3
|
| gptkbp:chemicalFormula |
contains morpholine ring
contains oxazolidinone ring |
| gptkbp:contraindication |
uncontrolled hypertension
concurrent use with monoamine oxidase inhibitors (MAOIs) |
| gptkbp:developedBy |
gptkb:Pharmacia_&_Upjohn
|
| gptkbp:discoveredBy |
gptkb:Pharmacia_&_Upjohn
|
| gptkbp:drugClass |
oxazolidinone antibiotic
|
| gptkbp:eliminationHalfLife |
about 5-7 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C16H20FN3O4
|
| https://www.w3.org/2000/01/rdf-schema#label |
Linezolid
|
| gptkbp:indication |
gptkb:pneumonia
endocarditis bacteremia skin and soft tissue infections |
| gptkbp:interactsWith |
tyramine-containing foods
monoamine oxidase inhibitors (MAOIs) selective serotonin reuptake inhibitors (SSRIs) |
| gptkbp:legalStatus |
prescription only
patent expired |
| gptkbp:mechanismOfAction |
inhibits bacterial protein synthesis
binds to 23S rRNA of the 50S ribosomal subunit |
| gptkbp:metabolism |
non-enzymatic oxidation
|
| gptkbp:molecularWeight |
337.35 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
31%
|
| gptkbp:riskFactor |
myelosuppression
serotonin syndrome with serotonergic drugs |
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
gptkb:anemia
gptkb:serotonin_syndrome gptkb:optic_neuropathy peripheral neuropathy thrombocytopenia lactic acidosis |
| gptkbp:usedFor |
treatment of vancomycin-resistant Enterococcus (VRE)
treatment of methicillin-resistant Staphylococcus aureus (MRSA) treatment of infections caused by Gram-positive bacteria |
| gptkbp:WHOModelListOfEssentialMedicines |
included
|
| gptkbp:bfsParent |
gptkb:MRSA_infections
gptkb:MRSA_infection gptkb:Zentiva |
| gptkbp:bfsLayer |
7
|